Full Text
The Full Text of this article is available as a PDF (31.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med. 1991 Oct 31;325(18):1261–1266. doi: 10.1056/NEJM199110313251801. [DOI] [PubMed] [Google Scholar]
- Albers G. W., Amarenco P., Easton J. D., Sacco R. L., Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001 Jan;119(1 Suppl):300S–320S. doi: 10.1378/chest.119.1_suppl.300s. [DOI] [PubMed] [Google Scholar]
- Albers G. W., Hart R. G., Lutsep H. L., Newell D. W., Sacco R. L. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke. 1999 Nov;30(11):2502–2511. doi: 10.1161/01.str.30.11.2502. [DOI] [PubMed] [Google Scholar]
- Barnett H. J., Kaste M., Meldrum H., Eliasziw M. Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts. Stroke. 1996 Apr;27(4):588–592. doi: 10.1161/01.str.27.4.588. [DOI] [PubMed] [Google Scholar]
- Bousser M. G., Eschwege E., Haguenau M., Lefaucconnier J. M., Thibult N., Touboul D., Touboul P. J. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983 Jan-Feb;14(1):5–14. doi: 10.1161/01.str.14.1.5. [DOI] [PubMed] [Google Scholar]
- Dyken M. L., Barnett H. J., Easton J. D., Fields W. S., Fuster V., Hachinski V., Norris J. W., Sherman D. G. Low-dose aspirin and stroke. "It ain't necessarily so". Stroke. 1992 Oct;23(10):1395–1399. doi: 10.1161/01.str.23.10.1395. [DOI] [PubMed] [Google Scholar]
- Farrell B., Godwin J., Richards S., Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1044–1054. doi: 10.1136/jnnp.54.12.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FitzGerald G. A. Dipyridamole. N Engl J Med. 1987 May 14;316(20):1247–1257. doi: 10.1056/NEJM198705143162005. [DOI] [PubMed] [Google Scholar]
- Hart R. G., Harrison M. J. Aspirin wars: the optimal dose of aspirin prevent stroke. Stroke. 1996 Apr;27(4):585–587. doi: 10.1161/01.str.27.4.585. [DOI] [PubMed] [Google Scholar]
- Hass W. K., Easton J. D., Adams H. P., Jr, Pryse-Phillips W., Molony B. A., Anderson S., Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989 Aug 24;321(8):501–507. doi: 10.1056/NEJM198908243210804. [DOI] [PubMed] [Google Scholar]
- Hervey P. S., Goa K. L. Extended-release dipyridamole/aspirin. Drugs. 1999 Sep;58(3):469–477. doi: 10.2165/00003495-199958030-00007. [DOI] [PubMed] [Google Scholar]
- Lenz T. L., Hilleman D. E. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother. 2000 Nov;34(11):1283–1290. doi: 10.1345/aph.10079. [DOI] [PubMed] [Google Scholar]
- Lutomski D. M., Bottorff M., Sangha K. Pharmacokinetic optimisation of the treatment of embolic disorders. Clin Pharmacokinet. 1995 Jan;28(1):67–92. doi: 10.2165/00003088-199528010-00006. [DOI] [PubMed] [Google Scholar]
- Patrono C., Roth G. J. Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? Stroke. 1996 Apr;27(4):756–760. doi: 10.1161/01.str.27.4.756. [DOI] [PubMed] [Google Scholar]
- Slattery J., Warlow C. P., Shorrock C. J., Langman M. J. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 1995 Oct;37(4):509–511. doi: 10.1136/gut.37.4.509. [DOI] [PMC free article] [PubMed] [Google Scholar]